ROP18 Inhibitor Screening Data for Toxoplasmosis Treatment

40 compounds were screened for anti-Toxoplasma gondii efficacy targeting the ROP18 kinase. Compound 2 had a selectivity index of 8.9 and increased mouse survival by 55%, while compound 38 had an SI exceeding 29.2 and increased survival by 42%. Kun Yin published the dataset on figshare in April 2026.

Use Cases

• Identify promising drug candidates based on in vitro kinase inhibition data
• Evaluate compound efficacy based on in vivo survival rate and parasite burden metrics
• Assess chronic infection prevention based on brain cyst formation inhibition data

Strengths

• Includes specific efficacy metrics for two lead compounds, such as selectivity indices (8.9 and >29.2) and survival rate increases (55% and 42%)
• Mechanistic data on ROP18 inhibition and Irga6 accumulation is described
• Dataset size is 26.3 MB

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data may reflect methodological bias inherent to the specific virtual screening and in vivo assays

Provenance

Source

figshare

Collection Method

Virtual screening and subsequent in vitro and in vivo efficacy testing of 40 compounds.

Freshness

Last updated 2026-04-09 08:20:31; freshness should be verified